Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study Assessing TG-1000 in the USA

Next Previous
X
Search
Trial Profile

A Phase II Study Assessing TG-1000 in the USA

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TG-1000 (Primary)
  • Indications Influenza virus infections
  • Focus Therapeutic Use

    • Most Recent Events

    • 24 Dec 2020 According to a TaiGen Biotechnology media release, so far, the FDA has not proposed supplements.According to the requirements, this Phase II clinical trial will soon be accepted under the premise of Sino-US dual reporting.
    • 05 Dec 2020 New trial record
    • 19 Nov 2020 According to a TaiGen Biotechnology media release, the company has submitted the TG-1000 Phase II clinical trial plan to the US FDA, and the content is the same as the Phase II clinical trial to be conducted in China. The company the Sino-US dual report for the phase II of clinical trials. If it can pass the review, it will be able to support the direct application for the phase III in USA after the TG-1000 international pharmaceutical factory authorization is completed in the future.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top